Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SHE:301096)
49.30
+2.21 (4.69%)
Sep 30, 2026, 4:00 PM EDT
SHE:301096 Revenue
Hangzhou Bio-Sincerity Pharma-Tech had revenue of 143.98M CNY in the quarter ending June 30, 2026, a decrease of -29.29%. This brings the company's revenue in the last twelve months to 650.08M, up 6.71% year-over-year. In the year 2025, Hangzhou Bio-Sincerity Pharma-Tech had annual revenue of 677.99M, down -15.45%.
Revenue (ttm)
650.08M
Revenue Growth
+6.71%
P/S Ratio
8.22
Revenue / Employee
460.39K
Employees
1,412
Market Cap
5.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 677.99M | -123.94M | -15.45% |
| Dec 31, 2024 | 801.92M | -215.52M | -21.18% |
| Dec 31, 2023 | 1.02B | 410.04M | 67.51% |
| Jan 1, 2023 | 607.41M | 233.10M | 62.27% |
| Dec 31, 2021 | 374.31M | 167.06M | 80.61% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 54.82B |
| Zhejiang Int'l Group | 34.20B |
| Yifan Pharmaceutical | 4.97B |
| Zhejiang Jolly Pharmaceutical Co.,LTD | 3.21B |
| Shanghai Shenqi Pharmaceutical Investment Management | 1.84B |
| GuangYuYuan Chinese Herbal Medicine | 1.41B |
| Hangzhou Minsheng Healthcare | 854.51M |
| Chongqing Lummy Pharmaceutical | 748.94M |